Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific is supported by a diversified, high-growth portfolio that has reduced reliance on commoditized cardiac rhythm management devices and drug-eluting stents, while still delivering above-MedTech growth through strong execution in Cardiovascular and Med-Surg. Its outlook is further bolstered by rapid Electrophysiology momentum from Farapulse, constructive Watchman guideline support, and a deep pipeline of launches such as Farawave Ultra, ICE, and Seismiq, with 2027 revenue and EPS estimated at $22.03B and $3.40. Valuation also appears attractive, with shares trading at less than 15 times forward P/E versus about 21x for the sector, and the planned Penumbra acquisition plus tuck-in M&A adding optionality to future growth.

Boston Scientific is facing a tougher fundamental backdrop as the 8-day cybersecurity breach disrupted about 9% of revenue-producing days, with the analyst assuming some lost sales will not be recovered and cutting FY26 sales growth to 5.5%-6.5% reported and 5%-6% organic. Competitive pressure in LAAC and EP, along with Watchman-related clinical and guideline uncertainty, is driving a much weaker near-term outlook, including a projected Q3 sales decline of 7.1% y/y and adj. EPS of $0.58, while 2027 growth expectations were also reset lower. Margin pressure compounds the problem, with 2026 gross margin expected below 2025’s 70.6% and only 0-25 bps of operating margin expansion, suggesting execution missteps, pricing pressure, and foreign-exchange and emerging-market risks are undermining confidence.